Avalo Therapeutics shares are soaring after acquiring AVTX-009, a Phase 2-ready anti-IL-1β mAb. With $185 million in gross proceeds, Avalo aims to develop AVTX-009 for hidradenitis suppurativa and other chronic inflammatory indications. Chairman Garry Neil believes AVTX-009 holds immense potential in the multi-billion-dollar HS market.